
pmid: 33484774
handle: 20.500.14243/450171 , 2434/825203 , 10281/314811 , 11365/1286695 , 2158/1223058
pmid: 33484774
handle: 20.500.14243/450171 , 2434/825203 , 10281/314811 , 11365/1286695 , 2158/1223058
Little is known about the metabolic regulation of cancer stem cells (CSCs) in cholangiocarcinoma (CCA). We analyzed whether mitochondrial-dependent metabolism and related signaling pathways contribute to stemness in CCA.The stem-like subset was enriched by sphere culture (SPH) in human intrahepatic CCA cells (HUCCT1 and CCLP1) and compared to cells cultured in monolayer. Extracellular flux analysis was examined by Seahorse technology and high-resolution respirometry. In patients with CCA, expression of factors related to mitochondrial metabolism was analyzed for possible correlation with clinical parameters.Metabolic analyses revealed a more efficient respiratory phenotype in CCA-SPH than in monolayers, due to mitochondrial oxidative phosphorylation. CCA-SPH showed high mitochondrial membrane potential and elevated mitochondrial mass, and over-expressed peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α, a master regulator of mitochondrial biogenesis. Targeting mitochondrial complex I in CCA-SPH using metformin, or PGC-1α silencing or pharmacologic inhibition (SR-18292), impaired spherogenicity and expression of markers related to the CSC phenotype, pluripotency, and epithelial-mesenchymal transition. In mice with tumor xenografts generated by injection of CCA-SPH, administration of metformin or SR-18292 significantly reduced tumor growth and determined a phenotype more similar to tumors originated from cells grown in monolayer. In patients with CCA, expression of PGC-1α correlated with expression of mitochondrial complex II and of stem-like genes. Patients with higher PGC-1α expression by immunostaining had lower overall and progression-free survival, increased angioinvasion and faster recurrence. In GSEA analysis, patients with CCA and high levels of mitochondrial complex II had shorter overall survival and time to recurrence.The CCA stem-subset has a more efficient respiratory phenotype and depends on mitochondrial oxidative metabolism and PGC-1α to maintain CSC features.The growth of many cancers is sustained by a specific type of cells with more embryonic characteristics, termed 'cancer stem cells'. These cells have been described in cholangiocarcinoma, a type of liver cancer with poor prognosis and limited therapeutic approaches. We demonstrate that cancer stem cells in cholangiocarcinoma have different metabolic features, and use mitochondria, an organelle located within the cells, as the major source of energy. We also identify PGC-1α, a molecule which regulates the biology of mitochondria, as a possible new target to be explored for developing new treatments for cholangiocarcinoma.
Male, Indoles, Carcinogenesis, PGC-1α, Mice, SCID, Oxidative Phosphorylation, CCLP1; HUCCT1; OXPHOS; PGC-1α; SR-18292, Cholangiocarcinoma, Mice, Metformin/administration & dosage, CCLP1; HUCCT1; OXPHOS; PGC-1α; SR-18292;, Mice, Inbred NOD, Signal Transduction/drug effects, SR-18292, CCLP1, PGC-1?, Propanols/administration & dosage, Oxidative Phosphorylation/drug effects, Tumor, Electron Transport Complex II, Indoles/administration & dosage, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/antagonists & inhibitors, OXPHOS, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Progression-Free Survival, Metformin, Mitochondria, Treatment Outcome, Phenotype, Neoplastic Stem Cells, Epithelial-Mesenchymal Transition/drug effects, Electron Transport Complex II/metabolism, Tumor Burden/drug effects, 570, Epithelial-Mesenchymal Transition, 610, SCID, Transfection, Cell Line, HUCCT1, Neoplastic Stem Cells/metabolism, Cell Line, Tumor, Mitochondria/metabolism, Cholangiocarcinoma/drug therapy, Animals, Humans, Gene Silencing, Bile Duct Neoplasms/drug therapy, Carcinogenesis/drug effects, Xenograft Model Antitumor Assays, Bile Duct Neoplasms, Inbred NOD
Male, Indoles, Carcinogenesis, PGC-1α, Mice, SCID, Oxidative Phosphorylation, CCLP1; HUCCT1; OXPHOS; PGC-1α; SR-18292, Cholangiocarcinoma, Mice, Metformin/administration & dosage, CCLP1; HUCCT1; OXPHOS; PGC-1α; SR-18292;, Mice, Inbred NOD, Signal Transduction/drug effects, SR-18292, CCLP1, PGC-1?, Propanols/administration & dosage, Oxidative Phosphorylation/drug effects, Tumor, Electron Transport Complex II, Indoles/administration & dosage, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/antagonists & inhibitors, OXPHOS, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Progression-Free Survival, Metformin, Mitochondria, Treatment Outcome, Phenotype, Neoplastic Stem Cells, Epithelial-Mesenchymal Transition/drug effects, Electron Transport Complex II/metabolism, Tumor Burden/drug effects, 570, Epithelial-Mesenchymal Transition, 610, SCID, Transfection, Cell Line, HUCCT1, Neoplastic Stem Cells/metabolism, Cell Line, Tumor, Mitochondria/metabolism, Cholangiocarcinoma/drug therapy, Animals, Humans, Gene Silencing, Bile Duct Neoplasms/drug therapy, Carcinogenesis/drug effects, Xenograft Model Antitumor Assays, Bile Duct Neoplasms, Inbred NOD
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 132 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
